Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3
Tiziana Life Sciences Ltd - Common Shares (TLSA)
Company Research
Source: GlobeNewswire
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced results from studies using a nasal anti-CD3 monoclonal antibody in traumatic spinal cord injury (SCI). Spinal cord injury is a devastating global health issue with profound implications for both mortality and morbidity. The inflammatory response mediated by microglia is a critical component in the pathogenesis of SCI. In these studies, the preclinical model was subjected to a spinal cord injury and then was treated with nasal anti-CD3, resulting in notable advancements in motor functions. Furthermore, spinal cord injuries (SCIs) are complex neurotraumatic wounds affecting military Service members, their families, Veterans, and the general population. These are serious injuri
Show less
Read more
Impact Snapshot
Event Time:
TLSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TLSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TLSA alerts
High impacting Tiziana Life Sciences Ltd - Common Shares news events
Weekly update
A roundup of the hottest topics
TLSA
News
- Tiziana Life Sciences Announces Acquisition of Shares by Executive ChairmanGlobeNewswire
- Tiziana Life Sciences to Ring the Closing Bell at NasdaqGlobeNewswire
- Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical TrialGlobeNewswire
- Tiziana Life Sciences Announces Purchase of Shares by Chief Executive OfficerGlobeNewswire
- Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering [Yahoo! Finance]Yahoo! Finance
TLSA
Sec Filings
- 12/19/25 - Form 6-K
- 12/17/25 - Form 6-K
- 12/17/25 - Form 6-K
- TLSA's page on the SEC website